The DOI matches its Crossref record.
Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse
Abstract
The purpose of this study was to characterize the pharmacokinetics of gemtuzumab ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute myeloid leukemia (AML) in first relapse. Gemtuzumab ozogamicin is an antibody‐chemotherapeutic conjugate characterized as antibody‐targeted chemotherapy, consisting of an engineered human anti‐CD33 antibody (hP67.6) linked to a potent cytotoxic agent, N‐acetyl‐gamma calicheamicin DMH. The pharmacokinetics of gemtuzumab ozogamicin was evaluated in 59 adult AML patients in first relapse, enrolled in a phase II study. Plasma was collected following each dose at specified times, and the pharmacokinetics was characterized by measures of hP67.6, total calicheamicin derivatives, and unconjugated calicheamicin derivatives. After administration of the first 9 mg/m 2 dose of gemtuzumab ozogamicin, the pharmacokinetic parameters (mean ± SD) of hP67.6 following the first dose were as follows: peak plasma concentration, 2.86 ± 1.35 mg/L;AUC, 123 ± 105 mg·h/L;t 1/2, 72.4 ± 42.0 hours; and clearance, 0.265 ± 0.229 L/h. Increased concentrations were observed after the second dose and are believed to be due to a decrease in clearance by CD33‐positive blast cells, a result of the reduced tumor burden following the first dose. The concentration profiles of calicheamicin followed the same time course as hP67.6, evidence that calicheamicin remained conjugated to the antibody and delivered to leukemic cells. No relationship was found between plasma concentration and response at the recommended dose. The pharmacokinetics of gemtuzumab ozogamicin has been characterized in AML patients receiving doses at the proposed therapeutic level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Metadata
- Authors
- Dowell, J. A., Korth‐Bradley, J., Liu, H., King, S. P., & Berger, M. S.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2001-11
- Volume
- 41
- Issue
- 11
- Pages
- 1206-1214
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2039223287
- Cited by
- 158
- References
- 0
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. https://app.cochat.ai/papers/10.1177/00912700122012751
- The paper
- Dowell, J. A., Korth‐Bradley, J., Liu, H., King, S. P., & Berger, M. S. (2001). Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912700122012751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.